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A B S T R A C T
Background
Vaginitis due to Trichomonas vaginalis is one of the most common of sexually transmitted diseases. Trichomoniasis affects women
during pregnancy as well but it is not clearly established whether it causes preterm birth and other pregnancy complications.
Objectives
The objective of this review was to assess the effects of various treatments for trichomoniasis during pregnancy.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (14 January 2011).
Selection criteria
Randomized trials comparing anti-trichomonas agents during pregnancy. Trials including symptomatic or asymptomatic women with
trichomoniasis were eligible.
Data collection and analysis
Two review authors assessed eligibility and trial quality.
Main results
We included two trials with 842 pregnant women. In both trials around 90% of women were cleared of trichomonas in the vagina
after treatment. In the US trial, women with asymptomatic trichomoniasis between 16 and 23 weeks were treated with metronidazole
on two occasions at least two weeks apart. The trial was stopped before reaching its target recruitment because metronidazole was not
effective in reducing preterm birth and there was a likelihood of harm (risk ratio 1.78; 95% confidence interval 1.19 to 2.66). The
South African trial recruited women later in pregnancy and did not have the design and power to address adverse clinical outcomes.
We excluded two recent studies, identified for the current update, because they did not address the primary question.
1Interventions for trichomoniasis in pregnancy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Authors’ conclusions
Metronidazole, given as a single dose, is likely to provide parasitological cure for trichomoniasis, but it is not known whether this
treatment will have any effect on pregnancy outcomes. The cure rate could probably be higher if more partners used the treatment.
P L A I N L A N G U A G E S U M M A R Y
Interventions for trichomoniasis in pregnancy
Metronidazole is effective against a trichomoniasis infection during pregnancy, but may increase the risk of preterm and low birthweight
babies.
Trichomoniasis is a very common sexually transmitted infection. Symptoms include vaginal itching and discharge. It is not clear if
pregnant women with trichomoniasis are more likely to give birth preterm, or have other pregnancy complications. The review of two
trials, involving 842 women, found that the drug metronidazole is effective against trichomoniasis when taken by women and their
partners during pregnancy, but it may harm the baby due to early birth. One of the trials was stopped early because women taking
metronidazole were more likely to give birth preterm and have low birthweight babies. Further research into trichomoniasis treatments
for pregnant women is needed.
B A C K G R O U N D
Vaginitis due to Trichomonas vaginalis is probably the most com-
mon sexually transmitted disease. According to WHO the total
number of new cases of the four main STIs in 2005 was esti-
mated to be 448 million, broken down as, 101 million new cases
of Chlamydia, 88 million new cases of Neisseria gonorrhoeae, 11
million new cases of Syphilis, and 248 million new cases of Tri-
chomonas vaginalis. And at any point in 2005 there were 153 mil-
lion cases with Trichomonas vaginalis (WHO 2011). Infection is
characterized by green-yellow frothy vaginal discharge, dyspareu-
nia, irritation of the vulva and urethra causing vulvovaginal sore-
ness, itching and dysuria. The diagnosis is usually made on clini-
cal findings and identification of the parasite in wetmount smear.
Wetmount smear is a cheap and quick method whereby motile
protozoa are identified under the light microscope. More sensitive
techniques such as culture, immunofluorescence and enzyme im-
munoassay are also available although they are more costly, time
consuming and therefore not used very often in busy clinics, es-
pecially in developing countries (Lossick 1991).
It is not clear whether Trichomonas vaginalis infection during
pregnancy has any effect on adverse pregnancy outcomes. Con-
cern has been raised about the possibility of increasing the trans-
mission of HIV infection because of impairment of the vaginal
mucosal barrier. It may, however, be difficult to single out any mi-
cro-organism with regard to these adverse effects, as many types
of vaginitis are polymicrobial.
Metronidazole has been the main agent used in the treatment of
trichomoniasis since the 1960s. It is generally advised to with-
hold metronidazole treatment during pregnancy until after the
first trimester (Lossick 1991; Murphy 1994). In early pregnancy
other agents such as clotrimazole have been recommended as a
local application. Tinidazole, ornidazole and nimorazole are other
nitroimidazoles which are also effective against trichomonas. The
Cochrane review comparing the effectiveness of various treatment
options for trichomoniasis in nonpregnant women found metron-
idazole and other nitroimidazole group drugs effective in treating
the infection (Forna 2003). There were no major differences be-
tween different nitroimidazoles.
Trichomoniasis during pregnancy is a common occurrence in both
developing and developed countries, treated by various healthcare
professionals. The possible effects of trichomoniasis on pregnancy,
the effectiveness of different preparations and different routes are
potential areas of controversy. It is therefore important to docu-
ment the evidence from randomized trials regarding the effective-
ness and safety of various treatment protocols.
O B J E C T I V E S
To determine the effectiveness of various drug treatments for tri-
chomoniasis in pregnant women.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomized trial in which an attempt is made to compare
different forms of treatment for trichomoniasis during pregnancy.
Types of participants
Pregnant women with:
1. symptomatic trichomoniasis, diagnosed by either wetmount
smear or any other laboratory test in addition to clinical findings;
2. asymptomatic trichomoniasis, with a laboratory diagnosis.
Types of interventions
• Any treatment versus no treatment.
• Comparison of two different agents.
• Comparison of different doses of the same agent.
• Systemic versus local treatment.
• Single dose (including one day) versus longer (five to 10
day) treatment.
Types of outcome measures
Primary outcomes
• Adverse pregnancy outcomes such as preterm birth, low
birthweight and intrauterine infection.
• Parasitological cure confirmed by repeat testing after
treatment.
• Symptomatic relief (clearance of discharge, soreness,
itching).
• Side effects and complications of treatment.
• Recurrence of infection.
• Satisfaction with treatment.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (14 Jan-
uary 2011).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language restrictions.
Data collection and analysis
For the methods used when assessing the trials identified in the
previous version of this review, see Appendix 1
For this update we intended to use the current recommended
method to assess the methodological quality using The Cochrane
Collaboration’s tool for assessing risk of bias (Higgins 2008).How-
ever, the two trials did not meet the inclusion criteria for the re-
view.
Selection of studies
Two review authors (M Azhar (MA), AM Gulmezoglu (AMG))
independently assessed for inclusion all the potential studies that
were identified as a result of the search strategy. We resolved any
disagreement through discussion.
Data extraction and management
We designed a form to extract data. For eligible studies, MA and
AMG extracted the data using the agreed form. We resolved dis-
crepancies through discussion. We entered data into ReviewMan-
ager software (RevMan 2008) and checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Both review authors independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008). We resolved
any disagreement by discussion.
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(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to conceal
the allocation sequence and determined whether intervention al-
location could have been foreseen in advance of, or during recruit-
ment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomization;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear.
(3) Blinding (checking for possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered the studies to
be at low risk of bias if they were blinded, or if we judged that the
lack of blinding could not have affected the results.
We assessed the methods as:
• low risk, high risk or unclear risk of bias for participants;
• low risk, high risk or unclear risk of bias for personnel;
• low risk, high risk or unclear risk of bias for outcome
assessors.
(4) Incomplete outcome data (checking for possible attrition
bias through withdrawals, dropouts, protocol deviations)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported, the numbers included in the analysis at
each stage (compared with the total randomized participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or can be supplied by
the trial authors, we re-includedmissing data in the analyses which
was undertaken. We assessed methods as:
• low risk of bias;
• high risk bias;
• unclear risk of bias.
(5) Selective reporting bias
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other sources of bias
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in the Handbook (Higgins
2008). With reference to (1) to (6) above, we assessed the likely
magnitude and direction of the bias and whether we considered it
was likely to impact on the findings. We explored the impact of
the level of bias through undertaking sensitivity analyses.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes are
measured in the sameway between trials.We used the standardized
mean difference to combine trials that measure the same outcome,
but use different methods.
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Unit of analysis issues
The review focuses on individual randomized trials.
Dealing with missing data
For included studies, we noted the levels of attrition. As there was
just one trial for analysis of most outcomes, we have not carried
out sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on an
intention-to-treat basis, i.e. we attempted to include all partici-
pants randomized to each group in the analyses, and analyzed all
participants in the group to which they were allocated, regardless
of whether or not they received the allocated intervention. The
denominator for each outcome in each trial was the number ran-
domized minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if T² was greater than zero and either I² was greater than
30% or there was a low P value (less than 0.10) in the Chi² test
for heterogeneity.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2008). We used fixed-effect meta-analysis where
there was only one study per analysis and also for combining data
where it was reasonable to assume that studies are estimating the
same underlying treatment effect: i.e. where trials examined the
same intervention, and the trials’ populations and methods were
judged sufficiently similar.
R E S U L T S
Description of studies
We included two trials that differed in several ways. Ross 1983
was conducted in South Africa and included both asymptomatic
and symptomatic women, whereas Klebanoff 2001 included only
asymptomatic women attending antenatal clinics in 15 centres
across the USA.
The diagnosis was made by wetmount smear in the South African
trial and by culture in the US trial. The US trial was set to inves-
tigate whether treatment of asymptomatic trichomoniasis could
prevent preterm birth and the enrolment took place between 16
and 23 weeks, whereas in the South African trial enrolment was
much later in pregnancy. The dose of metronidazole used in the
US trial was double (2 g 48 hours apart) the dose used in the South
African trial and was repeated after two weeks.
In the South African trial, 225 out of the 376 (60%) antenatal
women tested were positive. In the US trial only 7.6% (2377/
31,157) of women were trichomonas positive.
Metronidazole was given to women for their partners to take in
both studies (Klebanoff 2001; Ross 1983).
Risk of bias in included studies
In Klebanoff 2001, adequate sequence generation was generated
by a computer while in the Ross 1983 study, sequence was not
generated and the method of alternate allocation was used which
is prone to selection bias.
Allocation
Klebanoff 2001 does not provide any information regarding the
allocation concealment and actual manner with which allocation
was made. In the South African trial, women were randomly as-
signed to the intervention and control group and no further in-
formation is available to judge if allocation concealment was done
(Ross 1983).
Blinding
In the Ross 1983 trial, the technicians assessing the parasite did
not have any knowledge of the source of specimen. The Klebanoff
2001 trial was double blind with the use of identical placebos.
Incomplete outcome data
The details relevant to attrition and exclusions were detailed in
Klebanoff 2001 and Ross 1983.
Selective reporting
The trials seem to be free of selective reporting (Klebanoff 2001;
Ross 1983).
Other potential sources of bias
The choice of alternate allocation in Ross 1983 make it prone to
selection bias.
Effects of interventions
Both trials, Ross 1983 and Klebanoff 2001, showed high rates of
parasitological cure (around 90%) following treatment. The risks
of preterm birth (risk ratio (RR) 1.78; 95% confidence interval
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(CI) 1.19 to 2.66) and low birthweight (RR 1.38; 95% CI 0.92 to
2.06) were increased in the metronidazole group in the US study
(Klebanoff 2001).
In the South African trial (Ross 1983) there were no differences
in mean birthweight, gestational age and the incidence of low
birthweight (12% in treated versus 11% in control) between the
two groups.
D I S C U S S I O N
Trichomoniasis is a troublesome infection which causes significant
discomfort and is associated with adverse pregnancy outcomes
(Cotch 1997; French 1999). The literature onmetronidazole treat-
ment duringpregnancy andpretermbirth is not conclusive.Hauth
1995 used metronidazole and erythromycin and Morales 1994
used metronidazole alone in women with bacterial vaginosis and
high risk of preterm birth; in both studies, preterm birth rates
were reduced. McDonald 1997 on the other hand did not find a
clinically or statistically significant difference in preterm birth rate
with metronidazole in women with bacterial vaginosis. The trials
excluded from the review where metronidazole was given in com-
bination with the other antibiotics for treatment of trichomoniasis
for sexually transmitted infection control and prevention of HIV
(Kigozi 2003) and for reduction of perinatal HIV transmission
due to chorioamnionitis (Stringer 2010) did not yield significant
differences in terms of preterm birth and low birthweight.
Summary of main results
Metronidazole is effective in clearing the trichomonas infection
in the vagina. The increased tendency towards preterm birth as
well as low birthweight in the intervention arm as compared to
the control arm (Klebanoff 2001) is difficult to explain and it is
unknown whether it is real or not.
Overall completeness and applicability of
evidence
The statistical assessment of evidence suggests that treatment of
trichomoniasis with metronidazole does not reduce the incidence
of preterm birth and delivery of low birthweight babies. Therefore
treatment may be encouraged keeping in view the effectiveness
of metronidazole in parasitological cure of trichomoniasis (Ross
1983) for mainly women who are symptomatic.
Quality of the evidence
Two of the trials included in the review show reasonable rates
of parasitological cure (Klebanoff 2001; Ross 1983) and this
could probably be improved if more emphasis is put on partner
treatment. Despite the association of Trichomonas vaginalis with
preterm birth and low birthweight, the US trial results suggest
that a protective effect on preterm birth and low birthweight is
unlikely. Surprisingly, there was an increase in preterm births in
women receiving metronidazole (Klebanoff 2001). The trial was
stopped because it was highly unlikely that the treatment would
be effective if all women would have been recruited. However, the
question of whether the drug actually increases the preterm birth
rate remains unanswered. Recruitment was stopped in one of the
trials after 617 women were randomized (32% of total planned
sample size) (Klebanoff 2001). The authors discuss the possible
reasons for an increase in preterm birth rate including the possibil-
ity of toxic substances being released from destroyed Trichomonas
and an unpredicted change in the vaginal flora triggered by the
high-dose metronidazole treatment. Whether inclusion of symp-
tomatic women would have changed the result is unknown. With
the limited evidence currently available, metronidazole treatment
of asymptomatic trichomoniasis infection does not seem to reduce
preterm birth or improve low birthweight while it does provide
parasitological cure for trichomoniasis infection. From a method-
ological point of view the results of prematurely stopped trials
should be interpreted cautiously as they can be misleading.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found no evidence to support the use ofmetronidazole
in pregnant asymptomatic women with trichomonas vaginalis. It
is not clear why metronidazole should cause adverse pregnancy
outcomes when it is effective in clearing the infection. Given that
Trichomonas vaginalis is a sexually transmitted infection with un-
pleasant symptoms and associated with adverse outcomes, includ-
ing facilitating HIV transmission (Sorvillo 2001), it would seem
prudent to treat symptomatic women during pregnancy.
Implications for research
Metronidazole, or nitro-imidazoles in general, are the first choice
agents against Trichomonas vaginalis. There are no other readily
availablemedications to replace this class of drugs for the treatment
of trichomonas infections. Metronidazole when given in combi-
nation with other antibiotics did not show decline in the rate of
pretermbirth or low birthweight. There are two research questions
that need to be answered:
1. whether the treatment of pregnant women with symptoms
(trichomonas vaginitis) is effective in reducing preterm birth;
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2. whether the adverse effect of increased preterm birth in
treated asymptomatic women with trichomonas observed in one,
prematurely stopped trial is real.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by year of study]
Ross 1983
Methods Randomization was by alternate allocation. Placebos were not used. Technicians doing
the parasitological assessments had no knowledge of the source of the specimens
Participants 376 women attending a midwife operated antenatal clinic. Women were enrolled in 2
groups. The first group included those who booked before 34 weeks; the second group
were initially uninfected but then found to be infected at 38 weeks. In each group women
were randomly allocated to treatment (110 women) and no treatment (115 women)
groups. 151 women were found not to be infected. This latter group was followed until
delivery but not included in either group
Interventions Benzoylmetronidazole 50 ml (2 g metronidazole equivalent) oral, single dose vs no
treatment.
An extra dose of the medication was given to the women to take to their partners and
they were asked to refrain from coitus until the follow-up visit.
Untreated symptomatic patients received symptomatic relief but details of the agent used
for symptomatic treatment are not given
Outcomes Perinatal outcome (mean birthweight, low birthweight).
Gestational age at delivery.
Parasitological follow-up at 1 and 4 weeks.
Notes Trichomoniasis was diagnosed by saline wetmount technique.
Loss to follow-up: 8/110 in metronidazole group lost at first control and a further 14
could not have outcome assessments because of delivery or loss to follow-up. In the no
treatment group 5/115 were lost to follow-up and a further 19 attended too irregularly
to assess parasitological diagnosis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients found to be infected were
randomly divided into two groups.”
Allocation concealment (selection bias) High risk None. Alternate allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Comment: probably done (technicians do-
ing the parasitological assessments had no
knowledge of the source of the specimens)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Probably done.
9Interventions for trichomoniasis in pregnancy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ross 1983 (Continued)
Selective reporting (reporting bias) Unclear risk Unknown because protocol is not accessi-
ble.
Other bias Low risk The study seems to be free of other types
of bias.
Klebanoff 2001
Methods Double-blind randomized controlled trial using identical placebos. Randomization se-
quence was generated by computer. The method of allocation concealment and random
allocation are not mentioned
Participants 617 asymptomatic women in 15 centres in the USA. Women were screened from 8
weeks until 23 weeks and enrolled between 16 to 23 weeks.
Exclusion criteria: increased vaginal discharge with symptoms, allergy to metronidazole,
current ethanol abuse, antibiotic therapy within the previous 14 days, an intention
to continue antenatal care or plan delivery outside catchment area, language barrier
precluding informed consent, planned antibiotic therapy before delivery, current or
planned cervical cerclage, preterm labor before screening, current or planned tocolytic
therapy, fetal death, major congenital abnormality, multiple gestation, medical illness
Interventions Metronidazole 2 g (250 mg capsules x 8) on randomization + 2 g after 48 hours repeated
after 2 weeks versus placebo (lactose) capsules.
The first treatment was before 23 weeks and the second between 24 to 29 weeks but at
least 14 days after the initial treatment
Outcomes Preterm birth (< 37 completed weeks) was the primary outcome
Notes 2 women were randomized without having trichomoniasis.
Compliance was around 80% in both groups.
11.8% of all women were lost to follow-up. The authors report that the proportion of
lost to follow-up was not significantly different between the 2 groups
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The urn method of randomiza-
tion, with stratification according to clini-
cal center, was used to create the computer-
generated randomization sequence”
Allocation concealment (selection bias) Unclear risk Likely but not described.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “After specimens were obtained,
the women were randomly assigned in a
double-blind manner to receive eight cap-
sules containing either 250 mg of generic
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Klebanoff 2001 (Continued)
metronidazole each or a lactose placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “In this study, 544 of the 617
women (88.2 percent) returned for the fol-
low-up visit and provided information on
side effects. The reasons for failure to return
were loss of contact (47 women), delivery
before the scheduled visit (16 women), re-
fusal to continue in the study (8 women),
and other reasons (2 women); there was no
significant difference between the groups
in the proportion of women who did not
return for a follow-up visit”
Selective reporting (reporting bias) Unclear risk The protocol is not accessible.
Other bias Low risk
vs: versus
Characteristics of excluded studies [ordered by year of study]
Study Reason for exclusion
Robinson 1965 This trial was excluded because it was not clear whether the comparisons had been made between randomized
groups. The authors extended a series of metronidazole treated pregnant and nonpregnant women to include a
group of women randomly allocated to a treatment and placebo. Consequently, there is an imbalance in the sample
sizes of 2 groups and it is not possible to identify randomized groups in the tables presented
Roos 1978 There was no randomized comparison.
Kigozi 2003 This study is excluded as it is a secondary analysis of a randomized trial designed for evaluation of interventions
for STD control for prevention of HIV. In this trial the intervention was a community-based trial of presumptive
treatment of several antimicrobials including metronidazole as antitrichomoniasis agent. Therefore, to receive the
treatment (or no treatment) the women were not required to have trichomoniasis in pregnancy. Also, the authors
have acknowledged that some women in the intervention arm were likely to have received (presumptive) treatment
before pregnancy
Stringer 2010 The trial is a secondary analysis of a randomized trial where the main comparison is the use of several antenatal
and intrapartum antibiotics for reduction of chorioamnionitis-related perinatal HIV transmission against no use
of antibiotics
HIV: human immunodeficiency virus
STD: sexually transmitted disease
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D A T A A N D A N A L Y S E S
Comparison 1. Metronidazole versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Preterm birth (< 37 weeks) 1 604 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [1.19, 2.66]
2 Low birthweight (< 2500 g) 1 604 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [0.92, 2.06]
3 No parasitological cure 2 703 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.08, 0.17]
4 Birthweight (kg) 1 208 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.24, 0.04]
5 Gestational age (weeks) 1 200 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.69, 0.09]
Analysis 1.1. Comparison 1 Metronidazole versus no treatment, Outcome 1 Preterm birth (< 37 weeks).
Review: Interventions for trichomoniasis in pregnancy
Comparison: 1 Metronidazole versus no treatment
Outcome: 1 Preterm birth (< 37 weeks)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Klebanoff 2001 60/315 31/289 100.0 % 1.78 [ 1.19, 2.66 ]
Total (95% CI) 315 289 100.0 % 1.78 [ 1.19, 2.66 ]
Total events: 60 (Treatment), 31 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0052)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.2. Comparison 1 Metronidazole versus no treatment, Outcome 2 Low birthweight (< 2500 g).
Review: Interventions for trichomoniasis in pregnancy
Comparison: 1 Metronidazole versus no treatment
Outcome: 2 Low birthweight (< 2500 g)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Klebanoff 2001 51/315 34/289 100.0 % 1.38 [ 0.92, 2.06 ]
Total (95% CI) 315 289 100.0 % 1.38 [ 0.92, 2.06 ]
Total events: 51 (Treatment), 34 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.3. Comparison 1 Metronidazole versus no treatment, Outcome 3 No parasitological cure.
Review: Interventions for trichomoniasis in pregnancy
Comparison: 1 Metronidazole versus no treatment
Outcome: 3 No parasitological cure
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Klebanoff 2001 20/269 168/260 74.6 % 0.12 [ 0.07, 0.18 ]
Ross 1983 6/83 61/91 25.4 % 0.11 [ 0.05, 0.24 ]
Total (95% CI) 352 351 100.0 % 0.11 [ 0.08, 0.17 ]
Total events: 26 (Treatment), 229 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 11.29 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
favors treatment favors control
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Analysis 1.4. Comparison 1 Metronidazole versus no treatment, Outcome 4 Birthweight (kg).
Review: Interventions for trichomoniasis in pregnancy
Comparison: 1 Metronidazole versus no treatment
Outcome: 4 Birthweight (kg)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ross 1983 99 3.1 (0.49) 109 3.2 (0.54) 100.0 % -0.10 [ -0.24, 0.04 ]
Total (95% CI) 99 109 100.0 % -0.10 [ -0.24, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Analysis 1.5. Comparison 1 Metronidazole versus no treatment, Outcome 5 Gestational age (weeks).
Review: Interventions for trichomoniasis in pregnancy
Comparison: 1 Metronidazole versus no treatment
Outcome: 5 Gestational age (weeks)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ross 1983 91 39.5 (1.5) 109 39.8 (1.3) 100.0 % -0.30 [ -0.69, 0.09 ]
Total (95% CI) 91 109 100.0 % -0.30 [ -0.69, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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A P P E N D I C E S
Appendix 1. Methods used to assess trials included in previous versions of this review
The following methods were used to assess Klebanoff 2001; Ross 1983.
Trials under consideration were evaluated for methodological quality and appropriateness for inclusion, without consideration of their
results.
Methodological quality was assessed in terms of adequacy of allocation concealment as described in Clarke 2000.
Included trial data were processed as described in Clarke 2000.
WH A T ’ S N E W
Last assessed as up-to-date: 7 March 2011.
Date Event Description
14 January 2011 New citation required but conclusions have not changed New author updated the review.
14 January 2011 New search has been performed Search updated. The two reports identified by a new
search did not meet the inclusion criteria for this review
(Kigozi 2003; Stringer 2010).
Both studies were the sub-analysis of trials designed for
other interventions including control of sexually trans-
mitted diseases for prevention of HIV (Kigozi 2003)
and for use of a combination of antibiotics for reduction
in perinatal HIV transmission due to chorioamnionitis.
Therefore both the studies were excluded as their ba-
sis and randomization was not based on trichomoniasis
and its treatment during pregnancy
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 2, 1996
Date Event Description
1 October 2009 Amended Search updated. One report added to Studies awaiting
classification (Kigozi 2003).
24 July 2009 Amended Contact details updated.
11 September 2008 Amended Converted to new review format.
15 January 2004 New search has been performed Search rerun but no new trials identified.
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(Continued)
24 May 2002 New citation required and conclusions have changed Substantive amendment
13 March 2002 New search has been performed Review updated with one new trial.
C O N T R I B U T I O N S O F A U T H O R S
Both authors contributed equally to the development of this update.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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Medical Subject Headings (MeSH)
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